ARCHIVES

FDA Expands Gleevec Indication For Children with Ph+ ALL

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

Abraxane Improves Progression-Free Survival Compared to Decarbazine In Stage IV Disease

November 30, 2012

Drugs and Targets: EU approves Imbruvica in MCL, CLL

October 24, 2014

NIH Reconsiders Closing A Meeting Of Advisory Group

January 13, 1995

In Brief: Angel Bradley To Head NCAB Subcommittee UCLA, USC Join In CCRU Grant Application

September 3, 1982

In Brief: No End Of The Year Hassle His Time – NCI Full Appropriation for FY 1977 Released

November 19, 1976

Cancer Researchers Ask Congress for Full Bypass Budge Funding

April 27, 1990